Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

You are here

Internationonal Tumour Board - Case-Based Discussion of Real-World Clinical Management of Patients with Progressive Metastatic Colorectal Cancer (R)

Fri 25 Sept / 17:00 - 19:00 / Hall A4

The multi-kinase inhibitor regorafenib is approved for treatment of patients with mCRC who were previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. In this symposium, experts share their real-world clinical experiences, using a case-based format, to guide appropriate patient selection and illustrate the clinical benefit of treatment with regorafenib. Proactive adverse event management strategies for patients receiving regorafenib treatment are also provided (G.MKT.SM.ON.10.2015.1417).


Search this site

Search form


Register to our E-Alert to stay informed of new clinical research and cases published on this platform.